Thrivent Financial for Lutherans Has $1.01 Million Stock Holdings in Astrana Health, Inc. (NASDAQ:ASTH)

Thrivent Financial for Lutherans lowered its stake in Astrana Health, Inc. (NASDAQ:ASTH) by 1.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,130 shares of the company’s stock after selling 487 shares during the period. Thrivent Financial for Lutherans owned 0.06% of Astrana Health worth $1,013,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ASTH. Charles Schwab Investment Management Inc. acquired a new position in shares of Astrana Health during the third quarter worth $25,945,000. The Manufacturers Life Insurance Company bought a new position in Astrana Health during the 3rd quarter worth $1,377,000. FMR LLC acquired a new position in Astrana Health during the 3rd quarter worth about $48,413,000. Quantbot Technologies LP bought a new stake in shares of Astrana Health in the 3rd quarter valued at about $244,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Astrana Health in the third quarter valued at about $573,000. Institutional investors own 52.77% of the company’s stock.

Astrana Health Trading Down 3.7 %

ASTH opened at $29.86 on Wednesday. The company has a fifty day moving average price of $33.63 and a two-hundred day moving average price of $41.58. Astrana Health, Inc. has a 1-year low of $23.12 and a 1-year high of $63.20. The company has a market cap of $1.50 billion, a P/E ratio of 22.97, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last issued its earnings results on Thursday, February 27th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). The firm had revenue of $665.21 million during the quarter, compared to the consensus estimate of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. Analysts predict that Astrana Health, Inc. will post 1.15 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on ASTH. Truist Financial cut their price objective on Astrana Health from $50.00 to $46.00 and set a “buy” rating on the stock in a research note on Tuesday, March 18th. Bank of America reduced their price objective on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. Stifel Nicolaus decreased their price objective on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, February 20th. Barclays initiated coverage on shares of Astrana Health in a report on Tuesday. They issued an “equal weight” rating and a $36.00 target price on the stock. Finally, Robert W. Baird decreased their price target on Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Astrana Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.29.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.